EUDA ends $10M at-the-market share offering program
EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC.
Rhea-AI Filing Summary
EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC. The company had the ability to offer and sell up to $10,000,000 of ordinary shares under an At The Market Offering Agreement and related prospectus supplements.
EUDA sent a termination notice for the ATM Agreement on June 5, 2026, with termination to take effect on July 22, 2026 after a 30-business-day period. The ATM Offering has been suspended effective June 10, 2026, and EUDA plans to file a prospectus supplement reducing the number of shares offered to zero. As of this report, no ordinary shares have been sold under the ATM program.
Positive
- None.
Negative
- None.
Key Figures
ATM capacity: $10,000,000 ordinary shares
Termination effective date: July 22, 2026
Suspension date: June 10, 2026
+3 more
6 metrics
ATM capacity
$10,000,000 ordinary shares
Maximum size of at-the-market offering under ATM Agreement
Termination effective date
July 22, 2026
Effective date of ATM Agreement termination after 30 business days
Suspension date
June 10, 2026
Date ATM Offering was suspended
Termination notice date
June 5, 2026
Date EUDA sent termination notice to Chardan
Business day period
30 business days
Notice period before ATM Agreement termination becomes effective
Shares sold under ATM
0 ordinary shares
Total shares sold under ATM Agreement and Filed Prospectus Supplements
Key Terms
At The Market Offering Agreement, prospectus supplement, Registration Statement on Form F-3, at-the-market offering
4 terms
At The Market Offering Agreement financial
"entered into an At The Market Offering Agreement (the “ATM Agreement”) with Chardan"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
prospectus supplement regulatory
"filed a prospectus supplement on each of June 24, 2025 and January 23, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Registration Statement on Form F-3 regulatory
"formed a part of the Company’s Registration Statement on Form F-3 (File No. 333-282723)"
A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.
at-the-market offering financial
"relating to the offer and sale of up to $10,000,000 ordinary shares in an “at-the-market” offering"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
FAQ
What did EUDA (EUDA) announce in its June 2026 Form 6-K?
EUDA announced it is suspending and terminating its at-the-market equity offering program with Chardan. The company will reduce the number of shares offered under related prospectus supplements to zero and confirmed that no ordinary shares have been sold under this ATM Agreement.
How large was EUDA’s (EUDA) at-the-market offering program?
The ATM program allowed EUDA to offer and sell up to $10,000,000 of ordinary shares. This capacity was established through an At The Market Offering Agreement with Chardan and related prospectus supplements filed in June 2025 and January 2026 under a Form F-3 registration statement.
When will EUDA’s (EUDA) ATM Agreement with Chardan terminate?
EUDA sent Chardan a written notice to terminate the ATM Agreement on June 5, 2026. Under the agreement’s terms, the termination becomes effective on July 22, 2026, which is thirty business days after the date of the termination notice sent by the company.
When did EUDA (EUDA) suspend its at-the-market offering?
EUDA suspended its at-the-market offering effective June 10, 2026. The suspension applies while the termination notice period runs, and the company also plans to file a prospectus supplement reducing the number of shares that may be offered under the ATM-related prospectus supplements to zero.
What registration statement supported EUDA’s (EUDA) ATM offering?
EUDA’s ATM offering was conducted under a Registration Statement on Form F-3, File No. 333-282723. That registration statement was filed on October 18, 2024 and declared effective on November 4, 2024, with later prospectus supplements describing the at-the-market share offering.
AI-generated analysis. How Rhea-AI works. Not financial advice.
